Dr. Steven C. Quay, M.D., Ph.D., is Chief Executive Officer and Chairman of the Board of Directors of Atossa Genetics, The Breast Health Company™ and joins eHealth Radio and the Cancer Prevention Channel. Dr. Quay has a total of 75 U.S. patents, 98 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA.
Listen to interview [audio player below] with host Eric Michaels & guest Dr. Steven Quay discuss the following:
- What led you to dedicate yourself to your area of research and/or practice?
- What new approaches to breast health is Atossa Genetics taking?
- What treatments or interventions are available if Atossa testing identifies an elevated risk of breast cancer?
- How does the cost for Atossa testing compare with mammograms and is it covered by insurance?
- How do patients find a provider for Atossa testing?
- What tip would you give to women to maintain their breast health?
Dr. Quay has served as Chief Executive Officer and Chairman of the Board of Atossa Genetics, Inc. since the Company was incorporated in April 2009. Atossa is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
Atossa Genetics, headquartered in Seattle, has developed and markets a hand held, FDA-cleared, clinically proven and peer-reviewed “Pap smear for the breast” for early detection of cancerous cells or pre-cancerous conditions non-invasively, in the physician’s office. Atossa’s ForeCYTE Breast Health Test can provide vital early-detection of cancerous or pre-cancerous conditions years before they can be detected by other means and without risks of radiation, especially in women younger than 50.
Prior to his work at Atossa, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc. from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). From December 2008 to April 2009, Dr. Quay was involved in acquiring the Company's assets and preparing the Company's business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the MASCT System.
Dr. Quay oversaw the clinical testing and regulatory filing of the MASCT device with the FDA that led to its ultimate marketing clearance. Including the patents for the MASCT System, Dr. Quay has a total of 75 U.S. patents, 98 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics.
Related Web Site: www.atossagenetics.com